Abstracts tagged "neuropsychiatric disorders"

Abstract Number: 0659 • ACR Convergence 2022
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
Joshua Reynolds¹, Chandra Mohan², Yaxi Li² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, TX
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…
Abstract Number: 0968 • ACR Convergence 2022
Neuropsychological Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-administered Multidisciplinary Questionnaire in a Monocentric Cohort
Eleonora Pedretti¹, Laura Andreoli¹, Liala Moschetti¹, Cecilia Nalli¹, Anna Molinaro², Jessica Galli², Elisa Fazzi², Franco Franceschini¹, Angela Tincani³, Paolo Airò⁴ and Maria Grazia Lazzaroni¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Unit of Child and Adolescent Neuropsychiatry, ASST Spedali Civili and University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy
Background/Purpose: In the last years, the rate of successful pregnancies has significantly increased in Systemic Sclerosis (SSc)1 women. However, the long-term outcome of their children…
Abstract Number: 1460 • ACR Convergence 2022
Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis
Omer Pamuk¹, Saja Ali² and Sarfaraz Hasni², ¹NIH/NIAMS, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: The diagnosis of neuropsychiatric lupus (NPSLE) is challenging due to its variegated presentation, absence of diagnostic biomarkers and radiological imaging. The NPSLE is further…
Abstract Number: 1663 • ACR Convergence 2022
Age-Dependent Expansion and Activation of Disease-Associated Microglia in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde¹, Caroline Shah¹, Miranda Gurra¹, Yidan Wang¹, Deborah Winter² and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Skokie, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multipe end organs, including the brain. Despite a prevalence of over 50% in…
Abstract Number: 2058 • ACR Convergence 2022
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Stefan Perera¹, Jiandong Su², Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, Joan Wither¹, May Choi⁶, Simone Appenzeller⁷, Dorcas Beaton⁸, Dennisse Bonilla², Patricia Katz⁹, Robin Green⁵, Michelle Barraclough¹⁰ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, São Paulo, Brazil, ⁸Institute for Work & Health, Toronto, ON, Canada, ⁹UCSF, San Rafael, CA, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…
Abstract Number: 2223 • ACR Convergence 2022
Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus
Julius Lindblom¹, Daniel Toro-Domínguez², Elena Carnero-Montoro², Maria Orietta Borghi³, Jessica Castillo⁴, Ellen Iacobaeus¹, Yvonne Enman⁵, Chandra Mohan⁴, Marta Alarcon-Riquelme², Guillermo Barturen² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, ⁴University of Houston, Houston, TX, ⁵Karolinska Institutet, Sundbyberg, Sweden
Background/Purpose: Involvement of the nervous system is a common but poorly understood manifestation of SLE, termed NPSLE. Although studies have reported varying prevalence estimates (Unterman…
Abstract Number: 2265 • ACR Convergence 2022
Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Henri Tiedge¹, ILHAM MUSLIMOV², Valerio Berardi², Stacy Stephenson³, Ellen M. Ginzler⁴, Anca Askanase⁵ and John Hanly⁶, ¹SUNY, Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, NY, ³SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, ⁴SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
Abstract Number: 0536 • ACR Convergence 2021
The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice
Gonzalo Gómez-Hernández¹, Nieves Varela¹, Harini Bagavant², Guillermo Barturen¹, Marta E. Alarcon-Riquelme¹ and Maria Morell¹, ¹GENYO.Center for Genomics and Oncological Research, Granada, Spain, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance and activation of the immune response. Clinical manifestations are heterogeneous and…
Abstract Number: 0540 • ACR Convergence 2021
Behavioral Deficits May Precede Influx of Brain-Infiltrating Macrophages in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde, Miranda Gurra, Yidan Wang, Sara Radecki and Carla Cuda, Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects many end organs including the brain. Despite a prevalence of over 50% in…
Abstract Number: 0881 • ACR Convergence 2021
Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach
Ann Clarke¹, John Hanly², Yvan St.Pierre³, Caroline Gordon⁴, Sang-Cheol Bae⁵, Juanita Romero-Diaz⁶, Jorge Sanchez-Guerrero⁷, Sasha Bernatsky⁸, Daniel Wallace⁹, David Isenberg¹⁰, Anisur Rahman¹¹, Joan Merrill¹², Paul R Fortin¹³, Dafna Gladman¹⁴, Murray Urowitz¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen Ginzler¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Susan Manzi²¹, Andreas Jnsen²², Graciela Alarcn²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane Kamen³², Anca Askanase³³ and Vernon Farewell³⁴, ¹University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Hanyang University Medical Center, Seoul, Republic of Korea, ⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ⁷Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ⁸McGill University, Montréal, QC, Canada, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Centre for Rheumatology, University College London, London, United Kingdom, ¹¹University College London, London, United Kingdom, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ¹⁶University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁹Raleigh Neurology Associates, Chapel Hill, NC, ²⁰Northwestern University, Chicago, IL, ²¹Allegheny Health Network, Wexford, PA, ²²Lund University, Lund, Sweden, ²³University of Alabama at Birmingham, Birmingham, AL, ²⁴Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁷Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Little is known about the economic burden of NP lupus. We estimated annual and cumulative direct and indirect costs (DC, IC) associated with NP…
Abstract Number: 1481 • ACR Convergence 2021
Malondialdehyde-acetaldehyde Antibodies Occur in Systemic Lupus Erythematosus and Associate Specifically with Neuropsychiatric Involvement
Rory Monahan, Michelle van Beukel, Nicole Borggreven, Margreet Kloppenburg, Tom WJ Huizinga, Gerda Steup-Beekman and Leendert Trouw, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease characterized by a global loss of self-tolerance. Although autoantibodies are an important hallmark of SLE,…
Abstract Number: 0345 • ACR Convergence 2021
Anti-MPP-1 Autoantibodies in Systemic Lupus Erythematosus: A Potential Biomarker for Neuropsychiatric Manifestations
Eugene Krustev¹, Katherine Buhler¹, Francesca Cardwell², Marvin Fritzler¹, Ann Clarke¹ and May Choi³, ¹University of Calgary, Calgary, AB, Canada, ²University of Waterloo, Burlington, ON, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) can involve the central (CNS) and peripheral nervous system (PNS). Several autoantibodies have been associated with CNS NPSLE including…
Abstract Number: 0473 • ACR Convergence 2021
Disease-Associated Microglia Are Implicated in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Hadijat Makinde¹, Shang-Yang Chen¹, Elise Mike², Chaim Putterman², Deborah Winter³ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Albert Einstein College of Medicine, Bronx, NY, ³Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome affecting multiple organs, including the brain. Though 50% of patients may experience neuropsychiatric symptoms (NPSLE),…
Abstract Number: 0285 • ACR Convergence 2020
CXCL13 Neutralization Reduces Neuropsychiatric Manifestations in MRL/lpr Mice
Michelle Huang¹, Ariel Stock¹ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Targeted treatments for neuropsychiatric systemic lupus erythematosus (NPSLE) remain challenging to develop due to the unclear pathogenesis of the disease. Our laboratory has previously…
Abstract Number: 0498 • ACR Convergence 2020
Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE Pathogenesis
Chaim Putterman¹, Elise Mike¹ and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: While the etiology of neuropsychiatric lupus (NPSLE) is not fully understood, blood brain barrier (BBB) disruption and localized neuroinflammation are potential mechanisms that contribute…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].